Compare PAYP & MEDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAYP | MEDP |
|---|---|---|
| Founded | 2018 | 1992 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9B | 14.9B |
| IPO Year | 2026 | 2016 |
| Metric | PAYP | MEDP |
|---|---|---|
| Price | $20.43 | $507.64 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 13 |
| Target Price | $25.54 | ★ $498.25 |
| AVG Volume (30 Days) | ★ 1.6M | 300.1K |
| Earning Date | 08-12-2026 | 04-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.98 |
| EPS | N/A | ★ 15.28 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $13.19 |
| Revenue Next Year | N/A | $7.75 |
| P/E Ratio | ★ N/A | $33.63 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.80 | $284.10 |
| 52 Week High | $24.89 | $628.92 |
| Indicator | PAYP | MEDP |
|---|---|---|
| Relative Strength Index (RSI) | 50.73 | 53.79 |
| Support Level | $19.93 | $489.09 |
| Resistance Level | $21.20 | $622.32 |
| Average True Range (ATR) | 1.31 | 18.20 |
| MACD | -0.14 | 1.23 |
| Stochastic Oscillator | 39.90 | 57.03 |
PayPay Corp is a Japan-based financial technology provider operating a digital finance platform that integrates payments, banking, credit, and investment services for individuals and businesses. Its platform connects users and merchants, facilitating a cashless ecosystem and providing an all-in-one solution for daily financial activities. The company operates in two reportable segments: i) Payment segment and ii) Financial service segment. The majority of the company's revenue is derived from the Financial service segment, which includes internet banking services, securities intermediary services and PayPay Point investment-related services, and loan management services. Geographically, it operates predominantly in Japan.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.